{"url_path":"/sec/engn/8-k/2026-08-11/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Events.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-08-11","source_url":"https://www.sec.gov/Archives/edgar/data/1980845/0001193125-26-344559-index.html","accession_number":"0001193125-26-344559","cik":"0001980845","ticker":"ENGN","issuer_name":"enGene Therapeutics Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1980845/0001193125-26-344559-index.html","primary_entity_key":"0001980845","primary_entity_name":"enGene Therapeutics Inc."},"word_count":62,"has_tables":true,"body_markdown":"## Item 8.01 Other Events.\n\nOn August 11, 2026, enGene Therapeutics Inc. (the “Company”) hosted a virtual key opinion leader (“KOL”) event to discuss emerging non-muscle invasive bladder cancer market research insights. A copy of the KOL presentation is filed herewith as Exhibit 99.1 to this Current Report on Form 8-K and the full text of the presentation is incorporated herein by reference."}